Search results
Showing 1021 to 1035 of 1516 results for patients and public
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]
In development Reference number: GID-TA11307 Expected publication date: 06 January 2027
Awaiting development Reference number: GID-TA11637 Expected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]
In development Reference number: GID-TA11553 Expected publication date: TBC
In development Reference number: GID-HTE10068 Expected publication date: 06 January 2027
In development Reference number: GID-TA11437 Expected publication date: TBC
Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)
Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Evidence-based recommendations on collagen injection for vocal cord augmentation. This involves injecting collagen into the affected vocal cord(s).
View recommendations for HTG79Show all sections
Sections for HTG79
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)
This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.